WillItSurvive
Medical technology and health companies · France

Doctolib

doctolib.fr ↗

Doctolib runs online booking and practice management for doctors across France and Germany.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: CNIL scrutiny of US-AI-vendor data routing and Paris antitrust appeal ruling
The call

Doctolib owns the booking network in France and is fighting for the same lead in Germany and the UK, while regulators and a falling valuation test how solid that lead really is.

Doctolib lets patients book appointments with doctors and helps medical offices run their schedules across France, Germany, and the UK. It is tough to copy quickly because hospitals and clinics spent years integrating it into their systems, governments have approved it for sensitive health data, and it would take competitors years to get the same regulatory sign-offs. AI tools that answer patient questions or make phone calls could steal some of Doctolib's smaller tasks, but cannot rebuild the massive network of 500,000 doctors and 90 million patients already using it. The biggest risk is if French regulators crack down on how Doctolib routes patient data to American AI companies, or if a rival builds a simpler system that the UK's National Health Service adopts instead.

Why
01
AI pressure: Generic AI phone assistants and consultation bots. AI could commoditize appointment scheduling and note-taking, but Doctolib built its own tools (Aaron.ai, Azure/Mistral summaries) to own that layer first. Could AI do the core job? Unlikely.
02
Bigger players: DocPlanner/Jameda in Germany; EMIS/TPP duopoly in UK. DocPlanner chips at German share while Doctolib pushes into a UK market EMIS and TPP already control almost completely. Could a giant copy it? No, they are blocked.
03
What protects it. 500,000 providers and 90 million patients locked into one booking network that took a decade to build and is hard to replicate fast.
What would change this call
CNIL opens formal investigation into US-AI-vendor data routing (flagged for mid-2026). Would show regulatory risk forcing costly re-architecture away from Microsoft/Google/Anthropic tools.
Paris Court of Appeal ruling on the tied-selling antitrust appeal. Structural unbundling remedies would show the moat is legally forced open.
DocPlanner/Jameda booking-share gains reported in Germany or France. Would show a peer rival converting Doctolib's network advantage into real share loss.
Key numbers
  • >60% of online bookings in France (2025)
  • ~€422M ARR by end of 2025 (2025)
  • Valuation fell 38% to €3.6bn in secondary sale (2026-04)
Named risks
  • French antitrust fine and appeal over exclusivity, tied selling, and MonDocteur acquisition. Severity: medium
  • CNIL scrutiny over patient data routing through US AI vendors Google, Microsoft, Anthropic since June 2026. Severity: high
  • Security researchers found weaknesses in claimed end-to-end encryption, disclosed Dec 2024, published Aug 2025. Severity: medium
  • Valuation dropped 38-40% in April 2026 secondary sale amid broader tech multiple compression. Severity: medium
  • UK expansion via Medicus faces entrenched EMIS/TPP duopoly holding ~99% NHS GP share. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
DocPlanner (Jameda)contestingRaised 500M+ euros, launched AI assistant Noa.ai in 2024, strong in Germany via Jameda
EMIS/TPP (UK NHS duopoly)contestingDoctolib entered UK via Medicus acquisition May 2026 against ~99% incumbent share (2024)
ZocdoccontestingComparable US booking model, $283M raised, not a direct European competitor
CGM (CompuGroup Medical)contestingLegacy EHR/billing player competing adjacent to Doctolib's practice-management suite
Questions people ask
Is Doctolib profitable in 2026?
Doctolib reportedly turned profitable in France, per Sifted's June 2026 reporting, though the company itself declined to confirm the figure. Group revenue was estimated at over 400M euros in 2024, with ARR approaching 422M euros by end of 2025, per analyst estimates.
Who owns Doctolib?
Doctolib is privately held and venture/growth-equity backed, with investors including General Atlantic, Eurazeo, Bpifrance, Accel, and Generation Investment Management. A 2026 secondary sale added ATHOS KG, GenIM, and A.P. Moller Holding as shareholders. No IPO has occurred as of July 2026.
Could AI replace Doctolib?
Unlikely soon. Doctolib's moat is a two-sided network of 500,000 clinicians and 90 million patients plus regulator-vetted integrations like its NHS-approved Medicus system (May 2026). Generic AI assistants could commoditize admin tasks like phone booking, but cannot replicate the booking network or compliance depth quickly.
Who is Doctolib's biggest competitor?
DocPlanner, which owns Jameda in Germany, is Doctolib's closest pan-European rival, having raised over 500M euros and launched its own AI assistant Noa.ai in 2024. In the UK, Doctolib's new Medicus unit faces the EMIS/TPP duopoly, which held about 99% of NHS GP core-system share in 2024.
Has Doctolib had layoffs?
No confirmed layoffs; headcount grew modestly. Revelio Labs data shows about 3,626 employees as of December 2025, up 2.2% year over year, though hiring slowed from pandemic-era surges as Doctolib prioritized profitability in 2023-24, per Sifted's June 2026 reporting.
Is Doctolib's valuation falling?
Yes. A secondary share sale around April 2026 saw employees and early investors sell about 300M euros of shares, implying a 3.6bn euro valuation, a 38-40% drop from the 5.8bn euro peak set in the March 2022 Series F round led by Eurazeo.
Timeline
  • 2026-07-02Consumer-protection check finds Doctolib insurance-filter issue still misleading German users
  • 2026-06-03French public scrutiny over Doctolib AI use of Google, Microsoft, Anthropic for patient data
  • 2026-05-06Doctolib acquires Medicus, first new NHS GP software approved in 25 years, entering UK
  • 2026-04-06Secondary share sale values Doctolib at 3.6bn euros, down 38-40% from 2022 peak
  • 2026-03-19Doctolib partners with Diginex Plan A, discloses 500K providers and 90M patients
  • 2025-11-06French Competition Authority fines Doctolib 4.665M euros for abuse of dominance
  • 2025-11Berlin Regional Court rules Doctolib misled publicly-insured German users on insurance filters
  • 2024-10Doctolib launches AI consultation assistant built on Azure OpenAI and Mistral Large
  • 2024-05-22Doctolib acquires Aaron.ai, AI phone-assistant maker serving about 3,500 doctors
  • 2022-03Doctolib raises 500M euro Series F led by Eurazeo, reaching 5.8bn euro valuation
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources